BFM
LEGN icon

Boothbay Fund Management’s Legend Biotech LEGN Stock Holding History

Boothbay Fund Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,000
Closed -$966K – 1917
2023
Q2 		$966K Buy
+14,000
New +$915K 0.02% 839

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Boothbay Fund Management's LEGN Position: Q1 2026 in Review

Boothbay Fund Management held its Legend Biotech (LEGN) position steady in Q1 2026 at 65,826 shares worth $1.19M. The position accounts for 0.02% of the portfolio, ranked #861.

Boothbay Fund Management first reported a position in LEGN in Q2 2023 and has held it in 4 quarters since. The position peaked at $1.43M in Q4 2025. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Boothbay Fund Management held 65,826 shares of Legend Biotech worth $1.19M as of Q1 2026.
  • Boothbay Fund Management left its Legend Biotech share count unchanged in Q1 2026.
  • Legend Biotech made up 0.02% of Boothbay Fund Management's portfolio in Q1 2026, its #861 holding.
  • Boothbay Fund Management first reported a position in Legend Biotech in Q2 2023 and has held it in 4 quarters since.
  • Boothbay Fund Management's Legend Biotech position peaked at $1.43M in Q4 2025.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.